ResMed (ASX:RMD) Non Operating Income: A$-75 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
96 GF Score
Price A$31.45
GF Value A$37.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Non Operating Income?

ResMed ASX:RMD +0.70% 96 Non Operating Income is A$-75 Mil as of Jun. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 96/100 and a GF Value™ of A$37.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. ResMed's Non Operating Income for the three months ended in Jun. 2026 was A$-2 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was A$-75 Mil.

ResMed Non Operating Income Related Terms

ResMed Non Operating Income Historical Data

* Premium members only.

The historical data trend for ResMed's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Non Operating Income Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.54 -4.40 -110.86 -21.42 -71.78

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.57 -36.91 -14.14 -22.29 -1.50
ASX:RMD
96GF Score
ResMed Inc ASX:RMD
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of A$-75 Mil mean?
ResMed (ASX:RMD) has a Non Operating Income of A$-75 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on ResMed and its competitors.
Is ResMed's Non Operating Income too high?
ResMed's current Non Operating Income is A$-75 Mil. Overall, ResMed has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Non Operating Income compare to MDLN and WST?
ResMed's Non Operating Income of A$-75 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Devices & Instruments company?
A good Non Operating Income depends on the Medical Devices & Instruments industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on ResMed and its competitors. ResMed's current Non Operating Income is A$-75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$37.15, compared to a current price of A$31.45 — trading 15.3% below its estimated fair value. The current Non Operating Income is A$-75 Mil. ResMed's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Non Operating Income is A$-75 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$31.45 is trading 15.3% below its estimated GF Value™ of A$37.15. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for ASX:RMD:

  • Non Operating Income: A$-75 Mil
  • GF Value™: A$37.15 vs. price of A$31.45 (15.3% below fair value)
  • GF Score™: 96/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
96GF Score

Get the complete analysis for ASX:RMD

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$31.45
Price
A$37.15
GF Value